Corvus Pharmaceuticals, Inc. (CRVS)
| Market Cap | 276.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.40M |
| Shares Out | 68.14M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,496,773 |
| Open | 4.420 |
| Previous Close | 4.430 |
| Day's Range | 3.840 - 4.530 |
| 52-Week Range | 1.750 - 10.000 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 16.33 (+302.71%) |
| Earnings Date | May 8, 2025 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ci... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price forecast is $16.33, which is an increase of 302.71% from the latest price.
News
Why Is Corvus Pharmaceuticals Stock Soaring On Friday?
Corvus Pharmaceuticals, Inc. CRVS on Thursday released new interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Offi...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts...
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, man...
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointe...
Corvus Pharmaceuticals: Now At Cruising Altitude
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising dev...
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conferen...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and N...
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership ...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effect...
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will ...
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo Data continue to demonstrate a favorable safety and ef...
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president a...
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The g...
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday.
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock wa...
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, Dece...
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases
Corvus Pharmaceuticals: The Market Likes The Story
Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates with...